RESUMO
In the present study, the in vitro cytotoxic effect of poly(ADPribose) polymerase (PARP) inhibitor alone and in combination with nabpaclitaxel was evaluated on human triplenegative breast cancer (TNBC) cell line MDAMB231 and human luminal A breast cancer cell line MCF7. For this purpose, cell index (CI) values obtained from xCELLigence RealTime Cell Analysis (RTCA) DP instrument, mitotic index (MI), labelling index (LI) and apoptotic index (AI) analysis among cell kinetic parameters were used. As a result of PARP inhibitor application, there was a significant decrease in CI, MI and LI and a significant increase in AI for all the experimental groups. After application of PARP inhibitor in combination with nabpaclitaxel, the CI values were decreased for both cell lines, and the differences between the control and all the experimental groups were statistically significant (P<0.01) for all applications. PARP inhibitor, alone or in combination with nabpaclitaxel offers a promising treatment modality in different breast cancer subtypes.